rheumatology

News in brief: Infliximab biosimilars are equivalent; New vertebroplasty MBS item; Hydroxychloroquine donation destroyed

Infliximab biosimilars are equivalent: review Biosimilar brands of infliximab are equally effective as the originator molecule, well-tolerated, safe, and comparable in terms of immunogenicity when used in rheumatic conditions, an Australian review has found. The literature review led by Queensland University researchers included 10 randomised clinical trials of biosimilar enrolling 2308 patients, and 13 observational ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic